Amneal Pharma (AMRX)
NASDAQ:AMRX
Want to see AMRX full AI Analyst Report?
Top Page
Amneal Pharmaceuticals
(NASDAQ:AMRX)
Select Model
Select Model
Rating:59Neutral
Price Target:
$14.50
▲(4.24% Upside)
Action:Reiterated
Date:06/07/26
The score is held back primarily by elevated balance-sheet risk (high debt and negative equity) despite improving profitability and cash generation. Technicals are supportive with strong trend/momentum, but valuation is relatively expensive (high P/E, no dividend yield provided). Corporate events are constructive (Kashiv biosimilars expansion and positive shareholder votes), adding modest support.
Positive Factors
Biosimilars expansion via Kashiv acquisition
The Kashiv deal is a structural move into higher‑growth, higher‑margin biosimilars and creates a vertically integrated global platform. This materially diversifies revenue away from commodity generics, targets a multi‑year $300B+ LOE opportunity and supports sustainable margin uplift and pipeline scale.
Negative Factors
Elevated leverage and negative equity
High absolute debt and negative equity materially constrain financial flexibility and raise refinancing risk. This capital structure limits the company's ability to absorb shocks, fund organic growth or pursue additional M&A without increasing leverage or diluting shareholders, a medium‑term structural constraint.
Read all positive and negative factors
Positive Factors
Negative Factors
Biosimilars expansion via Kashiv acquisition
The Kashiv deal is a structural move into higher‑growth, higher‑margin biosimilars and creates a vertically integrated global platform. This materially diversifies revenue away from commodity generics, targets a multi‑year $300B+ LOE opportunity and supports sustainable margin uplift and pipeline scale.
Read all positive factors
Amneal Pharmaceuticals (AMRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.89B
Dividend YieldN/A
Average Volume (3M)1.60M
Price to Earnings (P/E)41.2
Beta (1Y)0.85
Revenue Growth7.62%
EPS GrowthN/A
CountryUS
Employees8,300
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.38
Shares Outstanding319,022,800
10 Day Avg. Volume1,733,365
30 Day Avg. Volume1,596,538
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)-55.77
Price to Sales (P/S)1.31
P/FCF Ratio14.63
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue2.20
Enterprise Value/Gross Profit5.69
Enterprise Value/Ebitda10.70
Forecast
1Y Price Target
$17.25Price Target Upside24.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.99
Revenue Forecast (FY)$3.10B
Amneal Pharmaceuticals Business Overview & Revenue Model
Company Description
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized me...
How the Company Makes Money
Amneal makes money primarily by selling pharmaceuticals and related services across multiple revenue streams. (1) Generics: A significant portion of revenue comes from the sale of generic prescription drugs to wholesalers, distributors, pharmacies...
Amneal Pharmaceuticals Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Positive
The call highlighted a decisive strategic move — the Kashiv acquisition — that meaningfully expands Amneal's addressable market, vertical capabilities, and long‑term growth runway in biosimilars. Q1 results showed strong top‑ and bottom‑line execution (revenues +4%, adjusted EBITDA +19%, adjusted EPS +29%), margin expansion, specialty product momentum, and improving leverage. Near‑term challenges include transaction‑related cash/financing impacts, modest near‑term dilution and guidance cadence (some 2027 EBITDA conservatism), integration and execution risk inherent to complex biologics development, and required CapEx to scale capacity. On balance, the positives around scale, pipeline, synergies ($400M–$500M), and improved long‑term financial trajectory outweigh the short‑term costs and execution risks.Positive Updates
Strategic Acquisition Creating a Global Biosimilars Platform
Amneal announced agreement to acquire Kashiv BioSciences (upfront consideration $750M: 50% cash / 50% equity, ~8% dilution; up to $350M in milestone payments and potential royalties), creating a vertically integrated biosimilars leader with a combined pipeline of 20+ biosimilar programs and access to what management cited as more than $300M of biologic LOE opportunity over the next decade and a broader $100B+ U.S. opportunity across the portfolio.
Negative Updates
Near-Term Leverage Increase and Transaction Costs
Acquisition funding (cash + some additional debt) is expected to slightly increase net leverage to ~3.7x by end‑2026 (from 3.5x at end‑2025) and will create near‑term transaction and integration cash flow impacts before deleveraging resumes in 2027 and reaches below 3x by 2028.
Read all updates
Q1-2026 Updates
Positive
Negative
Strategic Acquisition Creating a Global Biosimilars Platform
Amneal announced agreement to acquire Kashiv BioSciences (upfront consideration $750M: 50% cash / 50% equity, ~8% dilution; up to $350M in milestone payments and potential royalties), creating a vertically integrated biosimilars leader with a combined pipeline of 20+ biosimilar programs and access to what management cited as more than $300M of biologic LOE opportunity over the next decade and a broader $100B+ U.S. opportunity across the portfolio.
Read all positive updates
Company Guidance
Amneal raised its stand‑alone 2026 outlook after reporting preliminary Q1 results showing total net revenue $723M (+4%), Affordable Medicines $423M (+2%) with segment gross margin 47.3% (+320 bps YoY), Specialty $133M (+23%) (CREXONT $21M; Brekiya $4.6M vs $1.6M in Q4’25), AvKARE $166M (‑4%) with AvKARE gross margin +690 bps YoY, Q1 adjusted EBITDA $202M (+19%) and adjusted EPS $0.27 (+29%); company gross margin was 42.9% in 2025 and management expects ~45% in 2026 (targeting mid‑ to high‑40s over time). The proposed Kashiv acquisition carries $750M upfront (50/50 cash/equity; ~ $29M stock ≈8% dilution), up to $350M of milestones, expected cumulative synergies of $400–500M, and combined net leverage ~3.7x adjusted EBITDA at end‑2026 (vs 3.5x end‑2025; March 2026 net leverage 3.5x vs 3.9x Mar‑2025) with deleveraging to below 3x by 2028; drug‑substance capacity is planned to scale from 26,000L in 2026 to 75,000L by 2028 with ~$30–50M/year CapEx for 2–3 years, a pipeline of 20+ biosimilar programs (3–5 developments/year), six commercial biosimilars expected by 2027, and combined 2030 targets of roughly $4.3–4.5B revenue (≈+$1.2B or +40% vs 2026), EPS ≈+$0.70 (≈+70% vs 2026) with biosimilars contributing about $1.0–1.3B by 2030; closing expected in a few months pending approvals.Amneal Pharmaceuticals Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
38
Negative
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.05B | 3.02B | 2.79B | 2.39B | 2.21B | 2.09B |
| Gross Profit | 1.18B | 1.14B | 1.02B | 863.87M | 791.46M | 768.97M |
| EBITDA | 626.02M | 603.87M | 439.77M | 500.78M | 440.21M | 401.10M |
| Net Income | 122.36M | 72.06M | -116.89M | -83.99M | -129.99M | 10.62M |
Balance Sheet | ||||||
| Total Assets | 3.54B | 3.68B | 3.50B | 3.47B | 3.80B | 3.94B |
| Cash, Cash Equivalents and Short-Term Investments | 197.66M | 310.87M | 112.42M | 93.74M | 27.80M | 247.79M |
| Total Debt | 2.70B | 2.74B | 2.59B | 2.75B | 2.85B | 2.88B |
| Total Liabilities | 3.59B | 3.67B | 3.55B | 3.41B | 3.59B | 3.57B |
| Stockholders Equity | -45.41M | -70.79M | -109.27M | 19.78M | 298.42M | 360.34M |
Cash Flow | ||||||
| Free Cash Flow | 205.28M | 269.93M | 220.11M | 276.39M | -25.50M | 194.09M |
| Operating Cash Flow | 303.86M | 339.99M | 295.10M | 345.58M | 65.10M | 241.82M |
| Investing Cash Flow | -116.17M | -112.26M | -63.00M | -69.19M | -174.31M | -194.18M |
| Financing Cash Flow | -49.44M | -31.53M | -211.79M | -212.57M | -106.62M | -138.12M |
Amneal Pharmaceuticals Technical Analysis
Positive
13.91
Price Trends
12.91
Positive
13.22
Positive
12.18
Positive
Market Momentum
0.44
Negative
76.74
Negative
90.20
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMRX, the sentiment is Positive. The current price of 13.91 is above the 20-day moving average (MA) of 12.92, above the 50-day MA of 12.91, and above the 200-day MA of 12.18, indicating a bullish trend. The MACD of 0.44 indicates Negative momentum. The RSI at 76.74 is Negative, neither overbought nor oversold. The STOCH value of 90.20 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMRX.
Amneal Pharmaceuticals Risk Analysis
Amneal Pharmaceuticals disclosed 58 risk factors in its most recent earnings report. Amneal Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Amneal Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $1.85B | 18.94 | 17.32% | ― | 37.03% | ― | |
68 Neutral | $894.65M | 11.61 | 10.23% | ― | -1.39% | -41.70% | |
63 Neutral | $2.62B | ― | -2.73% | ― | 16.29% | -145.12% | |
59 Neutral | $4.89B | 41.18 | -144.72% | ― | 7.62% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.55B | -0.85 | -50.65% | 8.48% | -3.62% | -932.84% | |
49 Neutral | $1.29B | -16.94 | 35.22% | ― | -4.47% | -178.26% |
* Healthcare Sector Average
AMRX
Amneal Pharmaceuticals
15.32
7.54
96.92%
PRGO
Perrigo Company
11.17
-14.05
-55.70%
SUPN
Supernus Pharmaceuticals
45.09
11.94
36.02%
ANIP
ANI Pharmaceuticals
81.85
19.07
30.38%
AMPH
Amphastar Pharmaceuticals
20.29
-5.76
-22.11%
ALVO
Alvotech
4.14
-5.97
-59.05%
Amneal Pharmaceuticals Corporate Events
Executive/Board ChangesShareholder Meetings
Amneal Shareholders Back Board, Pay and Auditor at Meeting
Positive
May 7, 2026
Amneal Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on May 6, 2026, where shareholders voted on director elections, executive compensation and the company’s auditor. All nominated directors, including Deb Autor, the Pat...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Amneal to Acquire Kashiv, Expanding Biosimilars Platform
Positive
Apr 22, 2026
On April 21, 2026, Amneal agreed to acquire 100% of Kashiv BioSciences for $375 million in cash, $375 million in stock and up to $350 million in milestone payments, plus royalties, in a deal expected to close in the second half of 2026 pending sha...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.